Your browser doesn't support javascript.
loading
Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted nutrition in patients with advanced cancer.
Alderman, Bryony; Allan, Lindsey; Amano, Koji; Bouleuc, Carole; Davis, Mellar; Lister-Flynn, Stephanie; Mukhopadhyay, Sandip; Davies, Andrew.
Afiliação
  • Alderman B; Royal Surrey County Hospital, Guildford, UK.
  • Allan L; Royal Surrey County Hospital, Guildford, UK.
  • Amano K; Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
  • Bouleuc C; Department of Supportive and Palliative Care, Institut Curie, Paris, France.
  • Davis M; Palliative Care Department, Geisinger Medical System, PA, Danville, USA.
  • Lister-Flynn S; St Catherine's Hospice, Crawley, UK.
  • Mukhopadhyay S; Department of Pharmacology, Burdwan Medical College, Burdwan, India.
  • Davies A; School of Medicine, Trinity College Dublin, Dublin, Ireland. andavies@tcd.ie.
Support Care Cancer ; 30(4): 2983-2992, 2022 Apr.
Article em En | MEDLINE | ID: mdl-34665311
ABSTRACT

PURPOSE:

The pro vision of clinically assisted nutrition (CAN) in patients with advanced cancer is controversial, and there is a paucity of specific guidance, and so a diversity in clinical practice. Consequently, the Palliative Care Study Group of the Multinational Association of Supportive Care in Cancer (MASCC) formed a Subgroup to develop evidence-based guidance on the use CAN in patients with advanced cancer.

METHODS:

This guidance was developed in accordance with the MASCC Guidelines Policy. A search strategy for Medline was developed, and the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were explored for relevant reviews/trials respectively. The outcomes of the review were categorised by the level of evidence, and a "category of guideline" based on the level of evidence (i.e. "recommendation", "suggestion", or "no guideline possible").

RESULTS:

The Subgroup produced 11 suggestions, and 1 recommendation (due to the paucity of evidence). These outcomes relate to assessment of patients, indications for CAN, contraindications for CAN, procedures for initiating CAN, and re-assessment of patients.

CONCLUSIONS:

This guidance provides a framework for the use of CAN in advanced cancer, although every patient needs individualised management.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Prova Pericial / Neoplasias Tipo de estudo: Guideline / Risk_factors_studies Limite: Humans Idioma: En Revista: Support Care Cancer Assunto da revista: NEOPLASIAS / SERVICOS DE SAUDE Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Prova Pericial / Neoplasias Tipo de estudo: Guideline / Risk_factors_studies Limite: Humans Idioma: En Revista: Support Care Cancer Assunto da revista: NEOPLASIAS / SERVICOS DE SAUDE Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido